Printer Friendly

ADVANCED TISSUE SCIENCES ANNOUNCES SENIOR DIRECTOR, CLINICAL PROGRAMS

ADVANCED TISSUE SCIENCES ANNOUNCES SENIOR DIRECTOR, CLINICAL PROGRAMS
    LA JOLLA, Calif., Sept. 30 /PRNewswire/ -- Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATIS) today announced that the company has appointed Gary D. Gentzkow, M.D., as senior director, clinical research, according to Bernard D. King, senior vice president, research and clinical development.  Gentzkow has had extensive experience directing clinical trials of biopharmaceuticals and most recently served as medical director for Staodyn Inc., a medical device company based in Colorado.
    "Gary brings over 15 years of clinical trial experience to Advanced Tissue Sciences, including wound-healing studies with growth factors and medical devices," said King.  "He will direct the clinical trials of Dermagraft(TM) for the treatment of severe burns and chronic skin ulcers, as well as clinical trials of all of our future tissue-engineered therapeutic products."
    Advanced Tissue Sciences is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications.  Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow and liver.
    -0-             09/30/92
    CONTACT:  James P. Linton, Ph.D., manager-investor relations of Advanced Tissue Sciences, 619-450-5707
    (ATIS) CO:  ADVANCED TISSUE SCIENCES INC. IN:  MTC SU:  PER ST:  CA -- SD003 -- X522  09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:214
Previous Article:PENNSYLVANIA LIQUOR CONTROL BOARD SELECTED EASTERN REGION CHAIN RETAILER OF THE YEAR
Next Article:QUAKER STATE REFINANCES $50 MILLION OF SENIOR DEBT
Topics:


Related Articles
ADVANCED TISSUE SCIENCES APPOINTS SENIOR VICE PRESIDENT, RESEARCH AND CLINICAL DEVELOPMENT
ADVANCED TISSUE SCIENCES AND NEOMORPHICS SIGN DEFINITIVE ACQUISITION AGREEMENT
ADVANCED TISSUE SCIENCES AND MITSUBISHI KASEI ENTER AGREEMENT TO EVALUATE DERMAGRAFT(TM) FOR WOUND HEALING IN JAPAN
ADVANCED TISSUE SCIENCES' DERMAGRAFT(TM) PATENT ISSUED COMPANY COMPLETES ENROLLMENT IN PIVOTAL CLINICAL STUDY
ADVANCED TISSUE SCIENCES INC. ANNOUNCES FILING OF REGISTRATION RELATING TO PUBLIC OFFERING OF 2,500,000 SHARES OF COMMON STOCK
ADVANCED TISSUE SCIENCES ANNOUNCES PUBLIC OFFERING OF 2,500,000 SHARES OF COMMON STOCK AT $8.00 PER SHARE
ADVANCED TISSUE SCIENCES FILES IDE FOR ADDITIONAL BURN PRODUCT
ADVANCED TISSUE SCIENCES' BOARD APPOINTS NAUGHTON PRESIDENT
Advanced Tissue Sciences to Discontinue Sales of Skin2(R) Testing Kits; Company to Focus Exclusively on Therapeutic Products
Advanced Tissue Sciences Appoints Ronald L. Nelson to the Board of Directors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters